SCHEMBL6319628

SCHEMBL6319628

O=C(O)c1cccc(-c2cccc3[nH]ccc23)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASH1L Q9NR48 1/20 0.67
PIK3CD O00329 3/20 0.51
MAPK1 P28482 1/20 0.51
MAP2K4 P45985 1/20 0.51
MAPKAPK3 Q16644 1/20 0.51
MAPK6 Q16659 1/20 0.51
FTO Q9C0B1 1/20 0.51
AURKA O14965 2/20 0.50
TPX2 Q9ULW0 2/20 0.50
KMO O15229 1/20 0.50
PIK3CB P42338 2/20 0.49
HPGDS O60760 2/20 0.48
PIK3CG P48736 1/20 0.48
PRKCI P41743 1/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24196046 0.86 ASH1L (0.65) ASH1LPIK3CDFTOPIK3CBHPGDS
SCHEMBL3661287 0.86 ASH1L (0.74) ASH1LPIK3CDMAP2K4FTOPIK3CB
SCHEMBL2947880 0.86 PIK3CD (0.57) ASH1LPIK3CDMAP2K4FTOAURKA
SCHEMBL12171947 0.83 ATR (0.49) ASH1LPIK3CDMAPK1MAP2K4MAPKAPK3
SCHEMBL8440311 0.82 ASH1L (0.60) ASH1LPIK3CDPIK3CBHPGDSPRKCI
SCHEMBL5830596 0.82 HPGDS (0.60) ASH1LPIK3CDFTOAURKATPX2
SCHEMBL6321711 0.80 ASH1L (0.60) ASH1LPIK3CDFTOPIK3CBHPGDS
SCHEMBL21004055 0.80 ASH1L (0.74) ASH1LPIK3CDMAPK1FTOPIK3CB
SCHEMBL30593676 0.80 ASH1L (1.00) ASH1LPIK3CDMAPK1PIK3CB
SCHEMBL19586716 0.80 ASH1L (1.00) ASH1LPIK3CDMAPK1PIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127266-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-04-28 US disclosed
US-11225480-B2 Malic enzyme inhibitors SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2022-01-18 US disclosed
US-20210115038-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) 2021-04-22 US disclosed
WO-2021074898-A1 MALIC ENZYME INHIBITORS SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2021-04-22 WO disclosed
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ASH1L 1883/4885PIK3CD 365/4885MAPK1 296/4885
US-20210115038-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 ASH1L 2683/4885PIK3CD 2594/4885MAPK1 1199/4885
US-11225480-B2 Malic enzyme inhibitors ME1, RNASE1, ME2 ASH1L 2739/4885PIK3CD 3514/4885MAPK1 378/4885
US-20220127266-A1 MALIC ENZYME INHIBITORS ME1, ME2, ME3 ASH1L 2683/4885PIK3CD 2594/4885MAPK1 1199/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ASH1L 1883/4885PIK3CD 365/4885MAPK1 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.